Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
NCT05641337Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart, linagliptin, metformin in diabetes mellitus (DM), sponsored by Huashan Hospital. Started Oct 2022; status: recruiting.
02
Drugs
insulin degludec + insulin aspartlinagliptinmetformin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05641337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641337.